Proscia Concentriq vs Vesta
Agilent announced on October 13, 2026 an agreement to acquire Proscia for up to $270 million, $240 million in cash at closing plus up to $30 million in earnout. The deal is pending and expected to close early in Agilent's fiscal 2027, so a clinical lab signing for Concentriq today signs before that closing. The product is Concentriq AP-Dx, with 510(k)s from February 2024 and August 2026 for viewing FFPE surgical pathology slides as an aid to primary diagnosis, plus SOC 2 Type II announced in December 2025. Frozen sections, cytology and non-FFPE hematopathology fall outside the indication.
A lab director picking a slide platform and a clinician ordering a BCG-response test are not choosing between Concentriq and Vesta. Valar says Vesta tests are performed in its own CLIA-certified laboratory, and the report goes back to whoever ordered it. Valar shows no public price, though its FAQ describes a Financial Access Program for patients.
Pathology · Reviewed November 2, 2026
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
Vesta
by Valar Labs
Lab test run in a CLIA lab: AI on routine bladder cancer slides predicts BCG response, ordered by urologists.
When to pick each one
Proscia Concentriq
- FDA 510(k)s for FFPE primary diagnosis, Hamamatsu and Leica scanners
- SOC 2 Type II announced December 2025
- Demo request only, Agilent sale pending
Vesta
- Urologist orders, report returns from Valar's lab, per Valar
- Bladder cancer BCG response test
- Financial Access Program for patients
Score
Each row shows points earned of points available under the published rubric.
Proscia Concentriq
40of 100
Vesta
16of 100
| Dimension | Proscia Concentriq | Vesta | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 0 / 18 | +18 |
| HIPAA / SOC2 / BAA | 6 / 10 | 0 / 10 | +6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 8.4 / 21 | -8.4 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 3 / 12 | +5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Proscia Concentriq
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Vesta
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Proscia Concentriq
FDA decisions
K261380 (opens in new tab)510(k)2026-08-05
Concentriq AP-Dx
K230839 (opens in new tab)510(k)2024-02-08
Concentriq Dx (marketed as Concentriq AP-Dx)
Vesta
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names Vesta.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Proscia Concentriq | Vesta |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | n/a | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.